The study tested the prevalence of graft vessel disease (GVD) in 54 paediatric heart transplant (HTx) patients (32 male, age 0-17 years) who underwent coronary angiographic investigations (Ns117). These were evaluated according to the Stanford classification and additional criteria (peripheral obliterations, diameter fluctuations, pathologic tapering) were applied for risk assessment (no GVDy minimal lesions, GVD without Stanford lesions, accelerated GVD). In H&E stainings from right ventricular endomyocardial biopsies (EMBs169) diagnosis of acute cellular rejection (ACR, ISHLT) and microvasculopathy were performed. Mild rejection was found in 43% (Ns44) and severe rejection in 7% (Ns7) of EMB early (1st year) and mild rejection in 31% (Ns32) and severe in 8% (Ns9) late ()3 years) after HTx. Microvasculopathy was present in 22% of EMB. Risk assessment of coronary angiographies showed no GVDyminimal disease in 25% (Ns29), GVD without Stanford lesions in 12% (Ns14) and different grades of accelerated GVD in 74% (Ns74) of studies. All patients dying due to cardiac related causes of death (Ns6, 3-12 years after HTx) had evidence of GVD. The data show GVD to be an important cause of late cardiac related deaths in this population.
Introduction
Graft vessel disease (GVD) is one of the predominant complications after adult and paediatric heart transplantation (HTx) and one of the most important predictors of patient mortality at )5 years after HTx w1,2x.
Since focal stenoses are not mandatory for its definition, Gao published the so-called Stanford classification of morphologic and distributional features of epicardial GVD in coronary angiographies w3x. Controversial discussion is held about the sensitivity of coronary angiography w4,5x. In children, serial coronary angiography has been suggested to identify those at risk for subsequent events related to GVD w6x. Intravascular ultrasound has been shown to be a reliable tool w5x, but its use in children is limited due to their small anatomy. Therefore, diagnosis of GVD still seems to lack a cost-effective, fast and reliable tool. This study tested the prevalence of epicardial and microvascular GVD in children by proposing additional angiographic criteria to the Stanford classification w3x, including a risk stratification system applied in the context of diagnosis of microvascu- lopathy in right ventricular endomyocardial biopsies (EMB), which may complement present diagnostic tools and also be useful in paediatric patients.
Materials and methods
This retrospective study considered 54 HTx patients (32 male, age 1-17 years), out of 124 paediatric patients transplanted between April 1986 and June 1999 at the Deutsches Herzzentrum Berlin, who underwent at least one coronary angiographic investigation (CA) and who survived more than 30 days. All patients without invasive diagnostic procedures (Ns70, exituss33) were excluded from further investigation. Because of the small number of heart lung transplanted patients (Ns6) only HTx children were submitted to further statistical analysis.
CA (Ns117, range 1-5, 19 patients (35%) with only one investigation) carried out between the 1st and the 9th year after HTx were evaluated in cross-section according to the Stanford classification w3x. As additional criteria, the presence of peripheral obliterations (yesyno), diameter fluctuations (irregularities of blood vessel walls, yesyno), pathologic tapering (yesyno) and calcifications were evaluated (Fig. 1) . Risk assessment of CA was based on pathomorphologic findings and graded as no evidence of GVDy minimal disease, GVD without Stanford lesions and At the Deutsches Herzzentrum Berlin, routine rejection surveillance is done by non-invasive monitoring of the intramyocardial electrocardiogram w8x. Because of the retrospective design of the study, the pool of right ventricular endomyocardial biopsies (EMB) was harvested due to different indications, i.e. suspected acute cellular rejection (ACR) or during routine right and left heart catheterisation with random biopsy. As a result, different numbers of EMB within different time periods after HTx were available for each patient. For this reason, similar time intervals after HTx were fixed and the mean rank of different rejection episodes per patient for each interval was calculated and submitted to further investigation. The biopsy samples (size 1-1.5 mm, Ns305) were fixed in 4% buffered Lillie formol, dehydrated and embedded in paraffin. Preparation of tissue sections was done by cooling and cutting the samples into slices (depth 3 mm) and then drying them on glass slides. The tissue sections were deparaffinated with xylol and rehydrated with alcohol (100%, 90%, 70% and distilled water), then stained with hemalaun (3 min) and differentiated with HCl alcohol. Finally eosin (2% in alcohol, 30 s) was applied. Light microscopic diagnosis (magnification =200) of ACR was performed according to the working formulation of the International Society for Heart and Lung Transplantation w9x and microvasculopathy was diagnosed by grading endothelial cell swelling and vessel wall thickening with regard to evidence of luminal obstruction w10x.
Immunosuppression was maintained with 2-4 mgykg cyclosporine (trough level 250 ngyml, enzyme immune assay), 0.1-0.5 mgykg prednisolone and 1-5 mgykg azathioprine (dependent on the white blood cell count). At the time period in which the study patients were transplanted (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , this regimen was standard practice at our institution and was maintained if well tolerated by the patient. In cases of ACR, 500 mg methyl prednisone (3-5 days) or ATG or OKT 3 (ongoing moderate or severe rejection) was administered intravenously.
All data were analyzed using descriptive statistics. Correlations were analyzed using Spearman's rank correlation. Nominal and ordinal scaled parameters were compared using the chi-square test and metric parameters were compared by means of the Mann-Whitney test. A P value -0.05 was considered to be significant.
Results
Within the 1st year after HTx no ACR was found in 50% (Ns52), mild rejection (ISHLT 1A-2) in 43% (Ns44) and severe rejection (ISHLT G3A) in 7% (Ns7) of EMB. Between the 2nd and 3rd year in 39% (Ns20) there was mild and in 14% (Ns10) of EMB there was evidence of severe ACR. Beyond the 3rd year no rejection was found in 57% (Ns60) of EMB, mild rejection in 31% (Ns32) and severe rejection in 8% (Ns9). ACR episodes were found predominantly within the 1st year after transplant, but there was also evidence of late severe ACR episodes beyond the 3rd year after HTx ( Table 2) .
The results of the CA investigations are shown in Table 3 . Evidence of diameter fluctuations was found in 86% of investigations and showed no time dependent dynamic. Pathologic tapering and peripheral obliterations were present in 77% and 54%, respectively, of studies done, with an increase of prevalence during post-transplant time. Evidence of focal stenoses was found only beyond the 7th year after HTx in -10% of CA. One third of investigations revealed evidence of type B1 lesions, with stable prevalence during the follow-up. Twenty to thirty percent of studies showed type B2 lesions without a time dependent pattern. In contrast to type B1 lesions, found predominantly in the left anterior descending artery, type B2 lesions were more frequently found in the right coronary artery, but neither finding was statistically relevant. Total number  16  15  16  18  16  18  18  117  100 GVDsgraft vessel disease, Time intervals: 5s7th-12th month, 6s2nd year, 7s3rd year, 8s4th year, 9s5th-6th year, 10s7th-8th year, 11sG9th year.
The results of risk assessment of CA are given in Table 4 . Twenty-five percent of CA studied were graded as showing minimal or no disease. GVD without Stanford lesions was present in 12% and evidence of different grades of accelerated GVD (with Stanford lesions) was found in 63% of investigations. Except in one patient, severe progressed GVD was present only beyond the 7th year after HTx. CA findings were stable in 33% (Ns18), progressed in 26% (Ns14) and even regressed in 6% (Ns3) of patients. According to their CA findings, patients were divided into a 'high risk' (Ns23, 43%) and a 'low risk' group (Ns31, 57%). The demographic data of these patients were similar and CA findings were independent of these data ( Table 5 ). The number of CA per patient in the 'low risk' group was 2.2"1.2 and in the 'high risk' group 2.4"1.6 (P not significant). In patients graded as low risk CA findings remained stable in 12 and in patients graded as high risk they remained stable in six patients. Regression (Ns3) was only evident in the low risk group. Progression was found in five patients graded as low risk and in nine patients graded as high risk (Ps0.040). Of the patients with only one coronary angiography, eleven were grouped as low risk and eight as high risk.
Long-term survivors (G5 years) showed macrovascular alterations in more than 2y3 of cases. The five-year survival rate was 92% and the 10-year survival rate 85%. One patient underwent re-HTx due to GVD 11 years after first transplant. In total, 10 patients died: two due to rejection (4, 12 years after HTx), three due to infections (3, 6, 8 years after HTx), one due to progressive graft failure (11 years after HTx), another due to acute myocardial infarction (3 years after HTx), two due to sudden cardiac deathy arrhythmias (6, 10 years after HTx) and one due to an unknown cause (6 years after HTx). Of those who died (Ns10), 20% had no evidence of GVDyminimal disease, 10% showed GVD without Stanford lesions and 70% had accelerated GVD. All patients dying due to cardiac related causes of death (Ns6) had evidence of GVD (Ps0.045). Here, two patients died due to ACR, another two patients died because of sudden cardiac deathyarrhythmias and two further patients died due to progressive graft failure and acute myocardial infarction. The survival rates of the patients in relation to their risk assessment are given in Fig. 2 . The survival of the patients in the low risk group was not different as compared to the high risk group.
No correlations were found between time point or severity of ACR history and the evidence of GVD. The number of EMB per patient in the low risk group was 6.1"8.7 and in the high risk group 4.2"4.2 (P not significant). Evidence of severe endothelial cell swelling was present predominantly within the first two months after HTx and accounted for 5% (Ns9) of EMB investigated. Vessel wall thickening with luminal obstruction was found constitutively in 2% of EMB per time interval and in total in 22% (Ns37) of EMB investigated ( Table 6 ). Of the patients graded angiographically as low risk 23% and of those graded as high risk 48% (Ns6) showed signs of microvasculopathy (Ps0.065). GVDsgraft vessel disease, Time intervals: 5s7th-12th month, 6s2nd year, 7s3rd year, 8s4th year, 9s5th-6th year, 10s7th-8th year, 11sG9th year. Fig. 2 . Survival analysis of cardiac deaths according to coronary angiographic risk assessment (Psnot significant). Values are given as number wNx, range or mean standard"deviation. BVADsbiventricular assist device, CMVscytomegalovirus, fsfemale, HTxsheart transplantation, LVADsleft ventricular assist device, msmale, nssnot significant, yrssyears.
Humoral rejection accounted for about 10% of EMB and was predominantly present within the first year after HTx.
Discussion
Graft vessel disease (GVD) after cardiac transplantation has been described as common and as starting as early in children as in adults w1,2x.
In this study, evidence of GVD was independent of demographic data (Table 6 ). However, these results must be rated carefully because of the retrospective design of the study. Even in prospective trials so-called risk factors are a matter of controversial discussion. This applies also to the role of acute cellular rejection (ACR) in the development of GVD in HTx patients w1,6x. In this study, there was no association between frequency and severity of ACR and the development of GVD but it is noteworthy that about half of the EMB were harvested due to clinically suspected acute cellular rejection, so that ACR may be 'over-represented' in the specimen pool. In published data, ACR with severe haemodynamic compromise has been described in 11% of paediatric patients by Pahl and colleagues w11x, and mild ACR has been found in 20% of a cohort analysis based on the ISHLT registry w12x. Published data show treated rejections within the first year after transplant to occur in 40% of patients w13x and to be slightly more frequent in paediatric than in adult HTx patients w14x.
Although intravascular ultrasound has been shown to be a highly sensitive diagnostic tool for GVD in adults w5x, routine availability in post-transplant management of children is limited due to the small anatomy of patients w5,15x. Therefore coronary angiography remains the standard diagnostic procedure for routine clinical practice. The so-called Stanford classification published in 1988 w3x was proposed as a standardized evaluation system for epicardial GVD in coronary angiographies. However, it is not used constitutively. The sensitivity of coronary angiography for the diagnosis of GVD is controversial w4,5x, and this may be due to some extent to variable evaluation systems. Therefore, we hypothesized that the sensitivity of coronary angiography may be increased by adding additional criteria to the Stanford classification, including a risk stratification model for coronary angiographic findings.
In this study, patho-morphologic findings of epicardial coronary arteries were frequent after paediatric HTx and were present in 50-85% of investigations. Evidence of pathologic tapering and peripheral obliterations rose during the post-transplant time. Less than 10% of coronary angiographic investigations were affected by focal stenoses, which occurred only in the later post-transplant time. One third of investigations revealed evidence of Stanford type B lesions. Usually, this high prevalence of GVD is found in intravascular ultrasonic investigations or in autopsy studies, even in paediatric patients with long-term follow up w1,15x. In contrast, published data concerning angiographically identifiable coronary alterations in HTx children suggest ECSsendothelial cell swelling, VWTsvessel wall thickening. Time intervals: 1sF1st month, 2s2nd month, 3s3rd month, 4s4th-6th month, 5s7th-12th month, 6s2nd year, 7s3rd year, 8s4th year, 9s5th-6th year, 10s7th-8th year, 11sG9th year. much lower incidences of 7% w15x. Here the data of the registry of the ISHLT show a prevalence of GVD in adult HTx survivors of 8%, 33% and 43% at one, five and seven years w14x, and in HTx children of 3%, 11% and 14%, respectively w13x.
According to the risk assessment model proposed here, 25% of coronary angiograms studied were graded as showing minimal or no disease and about 60% showed evidence of different grades of accelerated GVD (with Stanford lesions). Progression of lesions was present in almost one third of the studied patients and significantly more pronounced in the 'high risk' patients. This suggests prognostic impact of the risk stratification proposed here. The fact that survival was not different in the low risk group may be due to the small number of deaths in this population. All patients dying due to cardiac related causes of death (Ns6) had evidence of GVD. The leading causes of death in these cases were arrhythmias, progressive graft failure and acute myocardial infarction. Sudden and unexpected deaths in paediatric patients with GVD have also been described by others w15x. In contrast to the findings in the study presented here, where overall survival in patients with GVD was 71% (24y34), Pahl and colleagues described only nine of 58 (15%) patients with GVD surviving w15x.
The five-year survival rate in this study was 92% and the 10-year survival rate was 85%. These data show excellent survival in this study population, but it should be remembered that only patients with coronary angiographies were included in the study who survived more than 30 days.
In this study, there was a positive, but not-significant, association between the development of macrovasculopathy and microvasculopathy. This phenomenon is the subject of controversial discussion with regard to adult HTx patients w2,3x, whereas no data have been published concerning this topic in paediatric patients.
In conclusion, the development of macrovascular GVD after paediatric HTx is as frequent as in adult cardiac transplant patients. Lethal course of GVD in this study accounted for 1% of deaths 1-5 years and 6% )5 years after HTx and was less frequent than in adult patients (5% at one year, 15% at 1-3 years, 18% at 3-5 years and 16% at )5 years w14x). The additional criteria to the Stanford classification and the risk stratification system proposed complement present diagnostic tools and are also useful in paediatric patients.
